Background RB1 gene screening aids clinical management and genetic counselling in
INTRODUCTION
Retinoblastoma (RB:MIM #180200) is a childhood tumour of the developing retina that occurs with an estimated frequency of 1 in 15,000-20,000 live births. Retinal cells are fully differentiated by 2-3 years of age so that it rarely develops in older children. The time of diagnosis is important for vision preservation and survival. Early diagnosis is possible when there is a family history or predictive genetic testing, enabling targeted examination under anesthesia for at-risk children. There are two forms of RB: heritable (45-50%) and nonheritable (50-55%). All bilateral cases and 15-20% of unilateral cases are heritable.
Inheritance is autosomal dominant with high penetrance. Carriers of pathogenic changes are at increased risk for non -ocular tumours such as osteosarcomas and soft tissue sarcomas.
The retinoblastoma susceptibility gene RB1 (Genbank #L11910.1) is located on human chromosome 13q14 and its product (pRB) acts as a tumour suppressor. Non-functional pRB enables uncontrolled cell proliferation, and bi-allellic inactivation allows retinoblastoma initiation. The spectrum of RB1 alterations is broad and widely distributed across the gene (1) (2) (3) . The most common are single base substitutions (50-60%) such as missense, nonsense and splice site changes. Small length changes (30%) generating premature stop codons are associated with highly penetrant and expressive (bilateral, multifocal) retinoblastoma.
Missense codons, in frame deletions/insertions, promoter and some splicing changes are associated with a low penetrance phenotype (4) (5) (6) . In about 60-70% of tumours there is loss of heterozygosity (LOH). Whole genome sequencing analysis has added chromothripsis to the list of alterations affecting RB1 in around 3% of tumours (7) . A minority of sporadic, unilateral cases (around 1.5%), characterised by very early onset, can be caused by overamplification of the MYCN gene (8) .
The epigenetic change of promoter hypermethylation has been reported as a somatic alteration in 8-15% of retinoblastomas (2) (3) (9) (10) (11) (12) . Hypermethylation inhibits the binding of transcription factors (RBF-1 and ATF) to their recognition sites in the RB1 promoter causing reduced gene expression (11) . This audit aimed to establish the percentage of retinoblastomas with promoter hypermethylation in our cohort. Histopathological analysis of a small selection of age-matched promoter hypermethylation positive and negative tumours was carried out to see if there were any differences. We also tested 204 blood samples to confirm that promoter methylation is a somatic, tumour modification which does not occur in blood samples. We discuss some individual cases with unusual results and implications for patient management.
MATERIALS AND METHODS
The methylation status of CpG islands in the RB1 promoter (L11910.1; g.1691-g.2005) was tested by methylation specific PCR (MS-PCR) of bisulphite modified DNA. Bisulphite induced sequence differences between methylated/unmethylated DNA were detected by using primer sets for unmethylated and methylated DNA. MS-PCR was performed for 286 fresh tumours, 29 formalin fixed, paraffin embedded samples (FFPE) samples and 204 blood samples (plus another 34 blood samples taken from patients with hypermethylated tumours). Peripheral blood was collected into EDTA tubes and genomic DNA extracted using the phenol/chloroform method, the Zymo-G midi kit (Zymo Research), or the Qiagen Midi Kit (Qiagen). DNA was extracted from fresh frozen tumour samples using the Nucleon II kit (GE Healthcare) or the Zymo-G midi kit (Zymo Research). FFPE samples were extracted as previously described (13), or with the RecoverAll Total Nucleic Acid Isolation Kit (Ambion).
Sample collection and extraction
Kits were used according to the manufacturers' instructions.
DNA was quantified by NanoDrop analysis, and quality was also checked by amplification in triplex PCR reactions encompassing the first intron of the X-Y homologous gene Amelogenin (Xp22.31-p22.1; MIM #300391), the STR Rbi.2 in RB1 intron 2 (D13S153), and the VNTR RB1.20 in intron 20. These markers were also used to confirm sample identity and to determine loss of heterozygosity (LOH) for those tumours where blood samples were available for comparison.
Bisulphite modification
Bisulphite modification was carried out on 400-500ng of DNA using the EZ DNA Methylation-Gold Kit (Zymo Research) according to manufacturer's instructions. A positive control of 'CpGenome' globally methylated DNA (Merk-Millipore) was included. Modified DNA was eluted in 1XTE buffer (Sigma Aldrich) and used for MS-PCR amplification. Some samples were modified by a manual method (14) .
Methylation specific PCR (MS-PCR)
MS-PCR for RB1 was optimised in house. Primers (Table 1) were designed to be specific for either modified methylated sequences, or modified unmethylated sequences. Both the sense and antisense strands were tested. Wild-type primers (specific to the sense strand) were used to check for unmodified DNA bypassing the modification process. Each MS-PCR included a positive sample from a previous batch as a PCR control. Unmodified DNA and water samples were used as negative controls. Modified DNA from blood was included as a positive control for unmethylated samples. Amplifications were carried out using HotStar Taq (Qiagen) in a 20ul reaction mix containing 1ul modified DNA and 10 pmoles of each primer.
Agarose gel electrophoresis
Fifteen microlitres of PCR product were electrophoresed (100Volts for 1 hour) on a 1.5% agarose gel (Invitrogen) in X0.5 TBE buffer (National Diagnostics). Products were visualized using 0.5 ug/ml ethidium bromide (Sigma Aldrich) in the agarose and running buffer. All results were checked by two clinical scientists. Positive results for hypermethylation were confirmed in a different DNA aliquot. When a tumour was found to be positive then that patient's blood sample was also tested (where available).
Histopathological analysis
Tumours from eighteen age-matched (at the time of diagnosis) patients were assessed blindly and independently for histological features by two experienced pathologists. The samples were from tumours with homozygous methylation (n=3), heterozygous methylation (n=5), homozygous for other pathogenic changes (n=5) and heterozygous for other changes (n=5).
Features including tumour size, focality, differentiation, invasion, necrosis and calcification were verified upon review.
RESULTS
315 tumour DNAs were screened. 11.4% (2 FFPE and 34 FT) were positive for promoter hypermethylation. We previously reported a figure of 13.9% (27/194 samples) in a smaller cohort (2) . For 34 of the hypermethylated tumours, blood samples were also available. None of these cases were constitutively methylated. Additionally, 204 other blood samples (sporadic RB cases) were tested. One had promoter hypermethylation due to presence of mosaic X;13 translocation ( Table 2 ).
2/315 tumours had no RB1 alterations but exhibited MYCN amplification (15) . Typical, or known, RB1 pathogenic variants were detected in 274 of the remaining 313 samples (87.5%).
However, not all tumour samples received full RB1 screens, although all were tested for promoter hypermethylation. There was incomplete screening in 26 samples where DNA was from a FFPE tumour and/or was of poor quantity/quality (n=11), or when blood samples had been referred for screening and pathogenic germline RB1 variants were already identified (n=15). Only thirteen fully screened tumours had pathogenic variations missing (13/287; 4.5%). Only 1 tumour displayed RB1 promoter hypermethylation alongside two other pathogenic variants (1/274; 0.4%).
In the total tumour population with two RB1 alterations, 166/274 (60.6%) had LOH characterised by STR analysis and/or QF-PCR. A further 27 had whole RB1 gene deletions, which if counted as LOH would bring the number to 193/274 (70.4%). In 14/36 (38.9%) of the hypermethylated tumours there was LOH, and in a further 5 there was a whole RB1 gene deletion which if included gives a figure of 19/36 (52.8%). In the other samples hypermethylation was accompanied by a transition/transversion, or a small deletion. Table 3 details the other RB1 variations detected in hypermethylated tumours.
Histopathological analyses of a subset of age-matched (at diagnosis) tumours were carried out. Ten unmethylated samples were compared to eight with methylation. There were no distinguishing histological features (as used in tumour classification) between these two groups. Features assessed included the level of differentiation, extent of necrosis, calcification, choroid invasion, iris neovascularisation and synechia.
DISCUSSION
This study is an audit of the methylation status of the RB1 promoter in 315 retinoblastomas.
In 274 tumours where an adequate screen was possible, two RB1 inactivating changes were identified. We previously reported promoter methylation in 13.9% (27/194) of tumours (2) . Table 3 ). Usually, when there are two other pathogenic changes in retinoblastomas there is no promoter hypermethylation, and this exception may be due to the tumour being multifocal.
It was initially reported that RB1 hypermethylation is primarily associated with sporadic, unilateral retinoblastoma (12, (16) (17) , and 35/36 (97.2%) of our methylated tumours were from such patients. We also detected promoter methylation in one familial case [c.2359 C>T, p.(R787*)] and in a multifocal tumour with a germline variant (c.2490-1 G>A) ( Table 3, cases 36 and 4). Two other positive tumours were probably multifocal and may therefore be from germline mosaics (the changes were not detectable in blood). In a previous report of a hereditary retinoblastoma case with RB1 promoter methylation, the hypermethylation was also shown to be the 'second hit' (16) Case 28 was a sporadic, unilateral patient who developed a second tumour in the same eye.
The first tumour had homozygous methylation (with LOH extending beyond the 5' of RB1 but no hemizygosity) and no other detectable change. The second tumour displayed heterozygous methylation (not counted in cohort) despite also having LOH. Again, no other variant could be detected. We have seen two similar cases of LOH tumours having heterozygous methylation. We cannot be sure that there is a germline alteration involved here as the second tumour may have seeded from the first. If it was a seeded focus then the secondary tumour could be progressing by losing methylation and gaining other changes which drive growth more effectively. It has been suggested that a hypermethylationmediated block on differentiation may promote initial growth, but then later inhibit other processes which contribute to progression, and that cancer hypermethylator phenotypes have better clinical prognosis (19) (20) . There is a weak, alternative promoter for RB1 in intron 2. This is imprinted and can produce an alternative transcript from the unmethylated, paternal allele which inhibits the production of the full length product from that allele, leading to expression bias from the maternal allele (21) . Whether a predisposing variant is maternally or paternally inherited may cause a low/high penetrance phenotype due to activity at this promoter (22) . It is possible that tumours with promoter variants can initiate transcription from this region to overcome inhibition at the usual promoter. In a study of human hepatocellular carcinoma, 40% of specimens (16/40) showed hyper-or hypomethylation at the CpG island in RB1 intron 2 (23).
Loss of imprinting at this locus was considered an additional mechanism for deregulating RB1 expression.
We accept hypermethylation as a pathogenic variation in tumours which have been fully screened. However, in FFPE tumours where a full screen is not possible, another change could have been missed and it is recommended that this result is not used in patient management. Since this audit, homozygous methylation was detected in two sporadic, unilateral tumours with LOH, and where QF-PCR indicated a double deletion of the promoter region. Although MLPA analysis showed that RB1 had no copy number change, QF-PCR indicated that there was a double deletion from the promoter to intron 2. It is possible that small rearrangements altered primer binding sites for QF-PCR whilst still allowing the MLPA probes to bind (the probes will still bind after inversions/rearrangements so long as the probe sites themselves are still intact). Consequently, these findings cannot currently be used in patient management/counselling. 34 blood samples from methylation positive tumour patients were tested for RB1 promoter methylation, and all were negative. This suggests that this epigenetic variation is not transmitted through the germ line and it is somatic in origin. We identified RB1 methylation in one blood sample from a sporadic patient with dysmorphic/congenital abnormalities.
Karyotyping showed a reciprocal translocation between the long arms of one X chromosome and one chromosome 13. There were two cell lines -in one the X;13 translocation was balanced whilst the other was unbalanced. RB1 methylation is expected to be due to X chromosome inactivation spreading to chromosome 13 and inactivating an RB1 allele as previously reported (24) . We do not routinely screen blood samples from sporadic RB patients. We continue to test blood samples from patients with hypermethylated tumours. There is evidence that this type of epigenetic change could be heritable as in hereditary nonpolyposis colorectal cancer (26) .
There has also been a report suggesting a similar mechanism in a low penetrance RB family with biparental contribution to the RB phenotype, which displayed a promoter variant associated with methylation (27). As part of on-going quality checks we continue to test some tumours with two other pathogenic RB1 variants for promoter hypermethylation, and have yet to find another sample which also has promoter hypermethylation. n/a n/a LOH 19 14m n/a n/a LOH 20 28 n/a n/a LOH 21 18 n/a n/a LOH 22 45 n/a n/a LOH 23 42 n/a n/a LOH 24 3 n/a n/a LOH 25 43 n/a n/a LOH 26 36 n/a n/a LOH 27 32 n/a n/a LOH 28 36 Multifocal /seeding? n/a n/a LOH 29 36 n/a n/a LOH 30 24 n/a n/a LOH 31 20 n/a n/a LOH 32 36 n/a n/a delRB1 33 11 n/a n/a delRB1 34 18 n/a n/a delRB1 35 42 n/a n/a delRB1 36 12 g.162,237 C>T Familial/germline c.2359C>T p.(R787*) and delRB1
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